Cynosure Group LLC Decreases Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Cynosure Group LLC lowered its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,841 shares of the biopharmaceutical company’s stock after selling 3,601 shares during the quarter. Cynosure Group LLC’s holdings in Intra-Cellular Therapies were worth $905,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. The Manufacturers Life Insurance Company boosted its stake in shares of Intra-Cellular Therapies by 1.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,057 shares of the biopharmaceutical company’s stock valued at $1,614,000 after buying an additional 283 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Intra-Cellular Therapies by 13.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,522 shares of the biopharmaceutical company’s stock worth $1,648,000 after acquiring an additional 2,622 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Intra-Cellular Therapies by 3.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 323,208 shares of the biopharmaceutical company’s stock worth $23,649,000 after acquiring an additional 11,104 shares in the last quarter. Captrust Financial Advisors raised its holdings in shares of Intra-Cellular Therapies by 47.0% in the 3rd quarter. Captrust Financial Advisors now owns 8,050 shares of the biopharmaceutical company’s stock valued at $589,000 after purchasing an additional 2,572 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth $1,715,000. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price target for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. StockNews.com started coverage on shares of Intra-Cellular Therapies in a research report on Friday, March 28th. They issued a “hold” rating on the stock. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $132.00 price target (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Ten analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $106.08.

Intra-Cellular Therapies Trading Down 0.0 %

Intra-Cellular Therapies stock opened at $131.87 on Wednesday. The stock has a fifty day moving average price of $129.34 and a 200 day moving average price of $100.60. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The firm has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. As a group, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.